Parameter | Spain | Sweden | UK |
---|---|---|---|
Prevalence | |||
 Total number of individuals aged ≥18 (n) | 37,860,506 [36] | 7,772,932 [37] | 50,909,098 [38] |
 Prevalence of diagnosed asthma (%) | 3.5 [39] | 8.0 [41] | 6.1 [42] |
 Prevalence of diagnosed COPD (%) | 2.8 [40] | 7.0 [43] | 1.8 [42] |
Proportion of patients receiving ICS + LABA FDCs (%) | |||
 Asthma | 33.4 [39] | 50.0 [41] | 35.5 [44] |
 COPD | 33.7 [40] | 39.7 [43] | 35.5a |
Proportion of patients using commonly prescribed DPIs to administer ICS + LABA FDCs (%) | |||
 BF Turbuhaler® | 34.6 [30] | 74.7 [59] | 31.1 [30] |
 FS Accuhaler® | 37.3 [30] | 15.1 [59] | 25.2 [30] |
Prescription distribution of BF Turbuhaler® doses (%) | |||
 BF Turbuhaler® 80/4.5 μg | 3.4 [30] | 1.1 [30] | 8.6 [30] |
 BF Turbuhaler® 160/4.5 μg | 54.0 [30] | 48.5 [30] | 55.9 [30] |
 BF Turbuhaler® 320/9 μg | 42.7 [30] | 50.4 [30] | 35.5 [30] |
Prescription distribution of FS Accuhaler® doses (%) | |||
 FS Accuhaler® 100 μg | 5.9 [30] | 3.8 [30] | 11.5 [30] |
 FS Accuhaler® 250 μg | 40.1 [30] | 50.3 [30] | 25.5 [30] |
 FS Accuhaler® 500 μg | 54.0 [30] | 45.9 [30] | 63.0 [30] |